(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

CORRECTED VERSION

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
27 January 2022 (27.01.2022)

WIPO | PCT

(10) International Publication Number
WO 2022/020363 A9

(51) International Patent Classification:
A61K 9/16 (2006.01) *A61K 31/58* (2006.01)
A61K 9/20 (2006.01) *A61P 25/00* (2006.01)
A61K 31/573 (2006.01) *A61P 25/24* (2006.01)

(21) International Application Number:
PCT/US2021/042394

(22) International Filing Date:
20 July 2021 (20.07.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/054,070 20 July 2020 (20.07.2020) US

(71) Applicant: **SAGE THERAPEUTICS, INC.** [US/US]; 215 First Street, Cambridge, MA 02142 (US).

(72) Inventors: **WATSON, Paul, Steven**; 104 Gateridge Place, Carrboro, NC 27510 (US). **BERNER, Bret**; 4011 54 Avenue SW, Seattle, WA 98166 (US). **NARAYAN, Padma**; 9 Crescent Hill Avenue, Arlington, MA 02474 (US). **CHEN, Xiaoxia**; 78 Canterbury Hill Road, Acton, MA 01720 (US). **STUTZMAN, Todd, Anthony**; 12930 Earnshaw Street, Overland Park, KS 66213 (US). **MENG, Jianing**; 10245 Hickman Mills Drive, Kansas City, MO 64137 (US). **WILKERSON, Carolyn**; 14 Schoolhouse Road, Somerset, NJ 08873 (US). **JAIN, Raj, Ramnik**; 12490 Quivira Road, Apt #1121, Overland Park, KS 66213 (US).

(74) Agent: **DOYLE, Kathryn, D.**; Honigman LLP, 650 Trade Centre Way, Suite 200, Kalamazoo, MI 49002 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report (Art. 21(3))*
— *with information concerning authorization of rectification of an obvious mistake under Rule 91.3 (b) (Rule 48.2(i))*

(48) Date of publication of this corrected version:
10 March 2022 (10.03.2022)

(15) Information about Correction:
see Notice of 10 March 2022 (10.03.2022)

WO 2022/020363 A9

(54) Title: FORMULATIONS OF 19-NOR C3,3- DISUBSTITUTED C21-N-PYRAZOLYL STEROID AND METHODS OF USE THEREOF

(57) Abstract: This invention relates to a 19-nor C3,3-disubstituted C21-pyrazolyl steroid of formula (I) and pharmaceutical compositions thereof. Also disclosed herein are methods of making the pharmaceutical compositions of the 19-nor C3,3-disubstituted C21-pyrazolyl steroid of formula (I) and methods of using the 19-nor C3,3-disubstituted C21-pyrazolyl steroid of formula (I) or crystalline solid forms, pharmaceutically acceptable salts, and pharmaceutically acceptable compositions thereof.